Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1

Experimental Dermatology

Volumn 16, Issue 10, 2007, Pages 814-822

  Riemann, Helge ^a   Takao, Joe ^a   Shellman, Yiqun G ^a   Hines, Wirt A ^a   Edwards, Carl K ^a   Norris, David A ^a   Fujita, Mayumi ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Animal model; Immunotherapy; Melanoma; Vaccine; Yeast

Indexed keywords

HLA ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; MELANOMA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VITRO STUDY; MELANOMA; MOUSE; NONHUMAN; PROTEIN ENGINEERING; PROTEIN TARGETING; YEAST;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERFERON TYPE II; KAPLAN-MEIERS ESTIMATE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE; SPLEEN; TRANSFECTION; VACCINATION;

EID: 34548509913     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2007.00599.x     Document Type: Article

References (48)

1. Ries L A G, Melbert D, Krapcho M et al. SEER Cancer Statistics Review, 1975-2004,
2. Bethesda, MD: National Cancer Institute, 2007. http://seer.cancer.gov/ csr/1975_2001
3. DiFronzo L A, Wanek L A, Elashoff R, Morton D L. Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma. Ann Surg Oncol 1999: 6: 705-711.
4. Miller A J, Mihm M C Jr. Melanoma. N Engl J Med 2006: 355: 51-65.
5. Newman S L, Holly A. Candida albicans is phagocytosed, killed, and processed for antigen presentation by human dendritic cells. Infect Immun 2001: 69: 6813-6822.
6. Stubbs A C, Martin K S, Coeshott C et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 2001: 7: 625-629.
7. Lu Y, Bellgrau D, Dwyer-Nield L D et al. Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res 2004: 64: 5084-5088.
8. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007: 117: 1195-1203.
9. Fetsch P A, Marincola F M, Filie A, Hijazi Y M, Kleiner D E, Abati A. Melanoma-associated antigen recognized by T cells (MART-1): The advent of a preferred immunocytochemical antibody for the diagnosis of metastatic malignant melanoma with fine-needle aspiration. Cancer 1999: 87: 37-42.
10. Kawakami Y, Eliyahu S, Delgado C H et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A 1994: 91: 6458-6462.
11. Zhai Y, Yang J C, Spiess P et al. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother 1997: 20: 15-25.
12. Hoashi T, Watabe H, Muller J, Yamaguchi Y, Vieira W D, Hearing V J. MART-1 is required for the function of the melanosomal matrix protein PMEL17/GP100 and the maturation of melanosomes. J Biol Chem 2005: 280: 14006-14016.
13. Ribas A. Update on immunotherapy for melanoma. J Natl Compr Canc Netw 2006: 4: 687-694.
14. Nestle F O, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998: 4: 328-332.
15. Schneider J, Brichard V, Boon T, Meyer zum Buschenfelde K H, Wolfel T. Overlapping peptides of melanocyte differentiation antigen Melan-A/ MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1. Int J Cancer 1998: 75: 451-458.
16. Benlalam H, Linard B, Guilloux Y et al. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J Immunol 2003: 171: 6283-6289.
17. Castelli C, Storkus W J, Maeurer M J et al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8 + cytotoxic T lymphocytes. J Exp Med 1995: 181: 363-368.
18. Zarour H M, Kirkwood J M, Kierstead L S et al. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci U S A 2000: 97: 400-405.
19. Underhill D M, Ozinsky A. Phagocytosis of microbes: Complexity in action. Annu Rev Immunol 2002: 20: 825-852.
20. Kaisho T, Akira S. Dendritic-cell function in Toll-like receptor- and MyD88-knockout mice. Trends Immunol 2001: 22: 78-83.
21. Ozinsky A, Underhill D M, Fontenot J D et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci U S A 2000: 97: 13766-13771.
22. Xia Y, Vetvicka V, Yan J, Hanikyrova M, Mayadas T, Ross G D. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J Immunol 1999: 162: 2281-2290.
23. Engering A J, Cella M, Fluitsma D et al. The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells. Eur J Immunol 1997: 27: 2417-2425.
24. Tan M C, Mommaas A M, Drijfhout J W et al. Mannose receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells. Eur J Immunol 1997: 27: 2426-2435.
25. Lam J S, Mansour M K, Specht C A, Levitz S M. A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity. J Immunol 2005: 175: 7496-7503.
26. Colella T A, Bullock T N, Russell L B et al. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: Implications for tumor immunotherapy. J Exp Med 2000: 191: 1221-1232.
27. Disis M L, Shiota F M, Cheever M A. Human HER-2/neu protein immunization circumvents tolerance to rat neu: A vaccine strategy for 'self' tumour antigens. Immunology 1998: 93: 192-199.
28. Fong L, Brockstedt D, Benike C et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 2001: 167: 7150-7156.
29. Bevan M J. Helping the CD8(+) T-cell response. Nat Rev Immunol 2004: 4: 595-602.
30. Zaunders J J, Dyer W B, Wang B et al. Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection. Blood 2004: 103: 2238-2247.
31. Appay V, Zaunders J J, Papagno L et al. Characterization of CD4(+) CTLs ex vivo. J Immunol 2002: 168: 5954-5958.
32. Namekawa T, Wagner U G, Goronzy J J, Weyand C M. Functional subsets of CD4 T cells in rheumatoid synovitis. Arthritis Rheum 1998: 41: 2108-2116.
33. Williams N S, Engelhard V H. Identification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism. J Immunol 1996: 156: 153-159.
34. Zajac A J, Quinn D G, Cohen P L, Frelinger J A. Fas-dependent CD4+ cytotoxic T-cell-mediated pathogenesis during virus infection. Proc Natl Acad Sci U S A 1996: 93: 14730-14735.
35. Mach N, Gillessen S, Wilson S B, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 2000: 60: 3239-3246.
36. Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene 2003: 22: 3188-3192.
37. Heinzerling L, Burg G, Dummer R et al. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther 2005: 16: 35-48.
38. Heinzerling L, Dummer R, Pavlovic J, Schultz J, Burg G, Moelling K. Tumor regression of human and murine melanoma after intratumoral injection of IL-12-encoding plasmid DNA in mice. Exp Dermatol 2002: 11: 232-240.
39. Elzaouk L, Moelling K, Pavlovic J. Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. Exp Dermatol 2006: 15: 865-874.
40. Spitler L E, Grossbard M L, Ernstoff M S et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000: 18: 1614-1621.
41. Hunger R E, Brand C U, Streit M et al. Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant. Exp Dermatol 2001: 10: 161-167.
42. Schroder K, Hertzog P J, Ravasi T, Hume D A. Interferon-gamma: An overview of signals, mechanisms and functions. J Leukoc Biol 2004: 75: 163-189.
43. Nishikawa H, Kato T, Tawara I et al. IFN-gamma controls the generation/ activation of CD4+ CD25+ regulatory T cells in antitumor immune response. J Immunol 2005: 175: 4433-4440.
44. Riker A, Cormier J, Panelli M et al. Immune selection after antigen-specific immunotherapy of melanoma. Surgery 1999: 126: 112-120.
45. Kurnick J T, Ramirez-Montagut T, Boyle L A et al. A novel autocrine pathway of tumor escape from immune recognition: Melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage melan-A/MART-1 antigen through down-modulation of its promoter. J Immunol 2001: 167: 1204-1211.
46. Durda P J, Dunn I S, Rose L B et al. Induction of "antigen silencing" in melanomas by oncostatin M: Down-modulation of melanocyte antigen expression. Mol Cancer Res 2003: 1: 411-419.
47. Sigalotti L, Fratta E, Coral S et al. Intratumor heterogeneity of cancer/ testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'- deoxycytidine. Cancer Res 2004: 64: 9167-9171.
48. Chin L, Pomerantz J, Polsky D et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 1997: 11: 2822-2834.